BSG-005: A Novel Polyene Macrolide Antifungal Agent – Development and Therapeutic Potential

1. Executive Summary

BSG-005 (DrugBank ID: DB18014) is an investigational small molecule antifungal agent, specifically identified as a novel, chemically modified nystatin-like polyene macrolide. This agent is under development by Biosergen, originating from foundational research conducted at the Norwegian University of Science and Technology (NTNU) and SINTEF.[1] BSG-005 exhibits broad-spectrum fungicidal activity, achieved by binding to ergosterol in the fungal cell membrane, which leads to pore formation, disruption of membrane integrity, and subsequent cell death. Preclinical investigations have highlighted its potent activity against a diverse range of fungal pathogens, including strains resistant to existing antifungal classes.[3]

A primary differentiating characteristic of BSG-005 is its potentially superior safety profile, particularly concerning nephrotoxicity, when compared to established polyenes such as Amphotericin B. This improved safety has been suggested by preclinical data and further supported by initial findings from Phase 1a clinical trials in healthy volunteers.[3]